Organon Posts Strong Q3 2024 Financial Results
Company Announcements

Organon Posts Strong Q3 2024 Financial Results

The latest update is out from Organon ( (OGN) ).

Organon reported robust financial results for Q3 2024, with a revenue increase to $1.582 billion, driven by strong performances in Women’s Health and Biosimilars. Nexplanon and Hadlima fueled growth, despite challenges from generic competition and pricing pressures. The company also narrowed its full-year revenue guidance, reflecting confidence in its strategic execution. Earnings per share rose significantly, benefiting from a tax asset valuation adjustment, highlighting Organon’s disciplined cost management and growth strategy.

Learn more about OGN stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskOrganon & Co. Reports Strong Third Quarter 2024 Results
TheFlyOrganon sees FY24 revenue $6.375 B – $6.425B consensus $6.38B
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App